Your shopping cart is empty

Subscriber login

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug GMP Report > Third-Party Manufacturing Concerns Draw CRL for Navidea’s Lymphoseek

Drug GMP Report

October 2012

Third-Party Manufacturing Concerns Draw CRL for Navidea’s Lymphoseek

The FDA has sent Navidea a complete response letter (CRL) on its Lymphoseek injection, citing concerns over quality control at third-party contract manufacturing facilities.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Drugmakers’ Shortage Prevention Programs Coming Up Short: Survey FDA’s Long-Awaited CMO Guidance Advises Use Of Quality Agreements Ranbaxy Compliance Reforms Reflect FDA Manufacturing Recommendations Concerns with Contract Manufacturer Draw Complete Response for Allergan’s Levadex

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.